Cost-effectiveness models of pneumococcal conjugate vaccines: Variability and impact of modeling assumptions

Farkouh, R. A., Klok, R. M., Postma, M. J., Roberts, C. S. & Strutton, D. R., Oct-2012, In : Expert review of vaccines. 11, 10, p. 1235-1247 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Currently, 13-valent pneumococcal conjugate vaccine (PCV); and ten-valent PCV vaccine are marketed. Neither vaccine obtained regulatory approval based on efficacy trials, but instead were approved based on a surrogate end point: immunogenicity data measuring effective antibody levels. Therefore, direct measures of efficacy were unavailable at the time economic analyses were conducted. The authors systematically reviewed cost-effectiveness studies of ten-valent PCV and 13-valent PCV from the literature to analyze the methodologies and compare the assumptions made about vaccine effectiveness. The following three inputs were found the most variant across analyses: efficacy against acute otitis media; inclusion of indirect effects; and cross protection. These assumptions are discussed with regard to the validity of supporting data and implications on decision-making.

Original languageEnglish
Pages (from-to)1235-1247
Number of pages13
JournalExpert review of vaccines
Issue number10
Publication statusPublished - Oct-2012


  • acute otitis media, cost-effectiveness analysis, cross protection, herd effects, invasive pneumococcal disease, nontypable Haemophilus influenzae, PCV7, PCV10, PCV13, PHiD-CV, pneumococcal conjugate vaccine, pneumonia, ACUTE OTITIS-MEDIA, NONTYPABLE HAEMOPHILUS-INFLUENZAE, STREPTOCOCCUS-PNEUMONIAE, NASOPHARYNGEAL CARRIAGE, ECONOMIC-EVALUATION, UNITED-STATES, PROTEIN-D, PHID-CV, UNIVERSAL IMMUNIZATION, INFANT VACCINATION

View graph of relations

ID: 5750116